Company intelligence / Profile preview

Xenon Pharmaceuticals

Burnaby, British Columbia, Canadaxenon-pharma.com ↗
Ownership
Public · XENE
Employees
~251
Development stage
Other
01

Overview

Xenon's lead asset, azetukalner (formerly XEN1101), a Kv7 potassium channel opener, is in multiple Phase 3 trials for focal onset seizures and primary generalized tonic-clonic seizures. The company also plans to initiate a Phase 3 program in major depressive disorder. Previous studies have shown promising efficacy and safety data in epilepsy patients; long-term open-label extension studies are ongoing to further assess durability of effect and safety profile.

Therapeutic areas
PsychiatryNeurology
Modalities
Small molecule
Industry
Biotech
02

Drug pipeline

12 assets

azetukalner

3

11 more assets in the full pipeline.

Request access →
03

Partnerships

Collaborations with pharmaceutical partners for development/commercialization; specific partners not named in public sources but historical investors include Roche Venture Fund and Takeda Ventures
04

Financials

Market cap
$5.7B
Total revenue
$0
Enterprise value
$4.8B

Beyond the preview

Go deeper on Xenon Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenon Pharmaceuticals.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call